FOXM1 and ovarian cancer: As FOXM1 expression is frequently upregulated in ovarian cancer tissue and is suggested to support chemoresistance [22,23,36], we investigated whether an additional benefit can be achieved by combination of the first-line agent carboplatin with thiostrepton.